[1] Listed N. 1999 World Health Organization- International
Society of Hypertension Guidelines for the Management of
Hypertension. Guidelines Subcommittee [J]. J Hypertens,
1999,17(2):151-183.
[2] 刘明波,李镒冲,刘世炜,等.2010年中国人群高血压疾病负担[J].
中华流行病学杂志,2014,35(6):680-683.
[3] 王连平,苏建华,周国跃,等.社区高血压病管理中应用基本药物
的卫生经济研究[J].中国民间疗法,2017(3):75-77.
[4] Freeman WR. Treatment of conditions of abnormally in-creased intraocular pressure by administration of phospho-nylmethoxyalkyl nucleoside analogs and related nucleoside
analogs: US, US6060463[P]. 2000(16-17):1010-1076.
[5] 高润霖.中国心血管病报告(2014)[J].中华医学信息导报,2015,
30(16):15.
[6] 王姝娟.健康教育在社区卫生服务中心高血压病管理中的应用
[J].世界中医药,2015,3(1):323.
[7] Primatesta P, Brookes M, Poulter NR. Improved Hyper-tension Management and Control: Results From the Health
Survey for England 1998 [J]. Hypertens, 2001,38(4):827-832.
[8] 刘宇婷,杜亚平.高血压社区管理研究的进展[J].中华全科医学,
2010,8(4):486-488.